Duygu Arslan Mehdiyev

Duygu Arslan Mehdiyev

Auto-generated profile, based on publicly available information

Duygu Arslan Mehdiyev

Ankara Etlik City hospital

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
MSMeryem Tuba Sönmez
Meryem Tuba Sönmez
Mehmet Fatih YetkinMehmet Fatih Yetkin
Mehmet Fatih Yetkin
DMDuygu Arslan Mehdiyev
Duygu Arslan Mehdiyev
Nazli DURMAZ CELİKNazli DURMAZ CELİK
Nazli DURMAZ CELİK
MEMerve Bahar Ercan
Merve Bahar Ercan
SMSemra Mungan
Semra Mungan
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Large language model-based chatbots are increasingly used by the public to access medical information. While these tools offer considerable potential in terms of accessibility and scalability, their accuracy, transparency, and clarity remain insufficiently evaluated for rare and diagnostically complex conditions such as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Objective: This study aimed to evaluate the quality, comprehensibility, transparency, and readability of responses generated by widely used AI chatbot platforms in response to a standardized, patient-centered question about MOGAD. Methods: We conducted a cross-sectional content analysis using the query: “What is MOGAD, and how is MOGAD treated?” Ten widely used chatbot platforms were selected to reflect diversity in architecture, access model, and functional design. Responses were collected on the same day, anonymized, and independently evaluated by seven blinded neurologists. Validated instruments were used, including DISCERN (treatment quality), PEMAT-P (understandability), Web Resource Rating (WRR; citation transparency), and two readability metrics: Flesch–Kincaid Grade Level (FKGL) and Coleman–Liau Index (CLI). Chatbots were also compared by access type (free vs paid) and functional focus (conversation-based vs search-based). Inter-rater reliability was assessed using intraclass correlation coefficients (ICCs). Results: Significant differences were observed across platforms in DISCERN, PEMAT-P, and WRR scores (all p < 0.001). Paid chatbots demonstrated higher treatment quality (p = 0.020) and citation transparency (p = 0.001) compared to free versions. Search-based models produced more understandable responses than conversation-based ones (p = 0.035). However, none of the chatbot responses achieved the recommended readability threshold for public-facing health communication (FKGL < 8). Inter-rater agreement was excellent across all expert-rated measures (ICC ≥ 0.838). Conclusions: AI chatbot responses to patient queries about MOGAD vary widely in quality, clarity, and transparency. These findings highlight the need for structured benchmarking, transparent evaluation frameworks, and thoughtful oversight in the use of generative AI tools for digital health communication, particularly in the context of rare and clinically complex diseases.

10 June 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
MSMeryem Tuba Sönmez
Meryem Tuba Sönmez
Mehmet Fatih YetkinMehmet Fatih Yetkin
Mehmet Fatih Yetkin
DMDuygu Arslan Mehdiyev
Duygu Arslan Mehdiyev
MKMesrure Köseoğlu
Mesrure Köseoğlu
SMSemra Mungan
Semra Mungan
RPRefik Pul
Refik Pul

15 September 2023 in Namık Kemal Tıp Dergisi
Verified
Journal Article
Closed access
DMDuygu Arslan Mehdiyev
Duygu Arslan Mehdiyev
ZAZeynep Özözen Ayas
Zeynep Özözen Ayas
GUGülgün Uncu
Gülgün Uncu

21 July 2023 in OSMANGAZİ JOURNAL OF MEDICINE
Verified
Journal Article
Open access
DMDuygu Arslan Mehdi̇yev
Duygu Arslan Mehdi̇yev
DADemet İlhan Algin
Demet İlhan Algin
GUGülgün Uncu
Gülgün Uncu
OEO.Osman Erdi̇nç
O.Osman Erdi̇nç

28 February 2026 in Eskisehir Medical Journal, Eskisehir City Hospital
Verified
Journal Article
Closed access
DMDuygu Arslan Mehdiyev
Duygu Arslan Mehdiyev
MSMeryem Tuba Sönmez
Meryem Tuba Sönmez
FTFunda Uysal Tan
Funda Uysal Tan
Introduction: Given the involvement of monocytes in multiple sclerosis (MS) pathogenesis, we aimed to compare the pan-immune-inflammation value (PIV) with the systemic immune-inflammation index (SII) in differentiating MS patients from healthy controls and in detecting relapse (attack) periods of disease activity. Methods: This case–control study included 43 newly diagnosed, treatment-naïve MS patients and 44 healthy controls. Blood neutrophil, lymphocyte, platelet, and monocyte counts were measured, and the SII and PIV values were calculated. Samples from patients with MS were collected during both the relapse and remission phases. SII and PIV were then compared between the patient and control groups and between relapse and remission states in the MS cohort. Results: Neither SII nor PIV differed significantly between patients with MS and healthy controls or between the relapse and remission phases (p>0.05 for all comparisons). In contrast, the median Expanded Disability Status Scale (EDSS) score was significantly higher during relapses than during remission (median 2.5 vs. 1.0, p<0.001), confirming greater disability during attack periods. Notably, although statistically non-significant, PIV yielded lower p-values than SII, which may indicate a weak trend requiring further study in larger samples. in the relapse vs remission comparison (PIV, p=0.261; SII, p=0.819). Conclusions: Hemogram-derived inflammatory indices, such as SII and PIV, appear insufficient for diagnosing MS or distinguishing relapses from remission. However, the consistently lower p-values observed with PIV suggest that it may be a slightly more sensitive marker than SII. Further large-scale studies, including both newly diagnosed and treated MS populations, are warranted to clarify the potential role of PIV in monitoring MS disease activity.

12 June 2026 in Clinical Eeg and Neuroscience
Verified
Journal Article
Closed access
DMDuygu Arslan Mehdiyev
Duygu Arslan Mehdiyev
NDNurhak Demir
Nurhak Demir
IÖİbRahim Öztura
İbRahim Öztura
BBBarış Baklan
Barış Baklan
Purpose: This study aimed to systematically assess ictal scalp electroencephalography (EEG) evolution by examining both ictal onset characteristics and late significant patterns (LSPs) in adults with focal epilepsy. We aimed to investigate their individual and collective descriptive roles in seizure lateralization and localization, as well as their correlation with seizure semiology, interictal EEG findings, and structural magnetic resonance imaging (MRI) within a multimodal presurgical assessment framework. Methods: We retrospectively analyzed 67 adults with drug-resistant focal epilepsy who underwent extended video-EEG monitoring, during which 242 seizures were documented. The ictal EEG findings were categorized based on the morphology of the onset and subsequent rhythmic patterns. The yields of lateralization and localization were evaluated independently for ictal onset patterns, LSPs, and combined ictal interpretations. Cohen's κ statistics were used to look at multimodal concordance between ictal EEG, seizure semiology, interictal EEG, and MRI findings. Results: The most common types of ictal onset were non-rhythmic or unclassifiable activity (29.3%) and low-voltage fast activity (28.5%). Late significant patterns were detected in 36.8% of seizures, predominantly manifesting as rhythmic theta–alpha activity, followed by repetitive spikes or sharp waves. The integration of LSPs resulted in enhanced lateralization and localization yields, in contrast to the analysis of onset patterns in isolation. At the individual patient level, combined ictal interpretation lateralized seizures in 68.6% of cases and localized seizure-onset regions in 70.1% of cases. There was a high degree of agreement between ictal and interictal EEG (κ = 0.775, strict right-left), a high degree of agreement between ictal EEG and MRI (κ = 0.710), and moderate-to-high agreement between ictal EEG and seizure semiology (κ = 0.647). Conclusion: A systematic evaluation of ictal EEG evolution, including the identification of LSPs, provides additional descriptive data that augments conventional ictal-onset analysis in focal epilepsy. The integration of ictal evolution findings with semiology, interictal EEG, and MRI validates a multimodal interpretative framework for presurgical evaluation. These results highlight the possible clinical importance of incorporating seizure evolution analysis into conventional scalp EEG interpretation, although further validation with surgical outcome data is required.